PDL Aims To Acquire New Royalty Assets Before Current Licenses Expire
This article was originally published in The Pink Sheet Daily
Executive Summary
PDL BioPharma has been preparing for the expiry of key patents by making a few hires and reconfiguring its business, with plans to use remaining cash either to purchase new royalty bearing assets or, failing that, to wind up the business.